Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 262 | 50% |
| 2020 | 1 | 151 | 51% |
| 2021 | 4 | 242 | 53% |
| 2022 | 1 | 262 | 56% |
| 2023 | 4 | 328 | 58% |
| 2024 | 4 | 325 | 59% |
| 2025 from claims | – | 1,093 884–1,284 | 59% |
| 2026 forecast | – | 1,216 952–1,527 | 58% |
| 2027 forecast | – | 1,330 986–1,758 | 58% |
| 2028 forecast | – | 1,454 1,029–2,007 | 58% |
| 2029 forecast | – | 1,590 1,081–2,280 | 58% |
| 2030 forecast | – | 1,739 1,139–2,581 | 58% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oregon; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 9% hospital outpatient, 87% surgery center, 4% office. The share outside the hospital has moved +17 pts since 2022, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~1,200 | ~82 | ~1,100 | ~48 |
| 2027 · ~1,300 | ~74 | ~1,200 | ~51 |
| 2028 · ~1,500 | ~73 | ~1,300 | ~54 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 91% (87% in 2025), hospital outpatient about 5% (9% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 35 | 2,932+9.5%/yr | +9.5%/yr | 0.8 | 78% | 6,310 in 2030+14%/yr |
| Arizona | 23 | 1,632+19%/yr | +19%/yr | 2.0 | 90% | 3,070 in 2030+11%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.7 | 55% | 1,090 in 2030+11%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.0 | 55% | 1,080 in 2030+13%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.8 | 20% | 790 in 2030+12%/yr |
| Nevada | 2 | 316−0.6%/yr | −0.6%/yr | 1.0 | 71% | 550 in 2030+9.6%/yr |
| Utah | 1 | 290+14%/yr | +14%/yr | 1.2 | 60% | 570 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 49 | 3,673+3.6%/yr | +3.6%/yr | 8.30.8× | 97% | 5,130 in 2030+5.7%/yr |
| Spinal cord & DRG stimulation | 11 | 336−6%/yr | −6%/yr | 0.71.2× | 95% | 480 in 2030+6.2%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
Mml leads with 45% of company spending on these surgeons in 2025, +8 pts on 2024.
In 2025, 10 companies reported engagement with Oregon’s surgeons worth $178K in consulting, speaking, meals and travel tied to these products, about $45K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.